NCT05152797View on ClinicalTrials.gov

Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

December 31, 2026

Conditions
Tumor Infiltrating Lymphocytes
Interventions
BIOLOGICAL

Autologous tumor-infiltrating lymphocytes

Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.

All Listed Sponsors
collaborator

Tongji Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Women's Hospital School Of Medicine Zhejiang University

OTHER

NCT05152797 - Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer | Biotech Hunter | Biotech Hunter